The Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND) for MGB Biopharma’s lead candidate MGB-BP-3, for the treatment of clostridium ...

In addition to being responsible for longer hospital stays and readmissions, Clostridium difficile is increases hospital costs by 40%, according to a new study conducted by Premier, Inc. Clostridium ...

Oral metronidazole and vancomycin have been compared to determine if one agent is more efficacious than the other. A prospective, randomized, controlled clinical trial compared metronidazole 250 mg ...

It has now been established that some 3,145 people contracted Clostridium difficile associated disease (CDAD) in Scottish hospitals in the six months between December 2007 and May 2008. Of these 285 ...

Objective: To describe emergent therapies, such as rifaximin, nitazoxanide, intravenous immunoglobulin (IVIG), tinidazole, tolevamer, and the possible use of a vaccine, in Clostridium ...

The FDA has issued a warning that the use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD). Healthcare professionals are ...

Clostridium difficile-associated disease (CDAD) is recognized as a major avoidable cause of morbidity and mortality among patients in hospital. Demographic changes and transfer of medical and surgical ...

Background: The association between the use of proton pump inhibitors and the risk of Clostridium difficile-associated disease (CDAD) is controversial. In this study we re-examined a previously ...

In the past, Clostridium difficile-associated disease (CDAD) was thought of mainly as a nosocomial disease associated with the use of broad-spectrum antibiotics, but its epidemiology seems to be ...

TUCSON, Ariz. and AUSTIN, May 2, 2019 -- The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Therapeutic Area Standard, which describes how to use CDISC ...